ArticleTheranostics2020
Self-accelerating H
Article in Theranostics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 59 citations in OpenAlex.
- Controlled Self-Assembly of Gold Nanoparticles for Photo-Enhanced Cancer Imaging and Treatment.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Emerging Nanoreactors for Precision Disease Treatment: From Principles to Biomedical Applications.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Sericin-coated MnOScientific reports · 2025Article
- Magnetic-susceptibility-dependent ratiometric probes for enhancing quantitative MRI.Nature biomedical engineering · 2025Article
- Selective enhanced cytotoxicity of amino acid deprivation for cancer therapy using thermozyme functionalized nanocatalyst.Journal of nanobiotechnology · 2024Article
- Glucose oxidase and metal catalysts combined tumor synergistic therapy: mechanism, advance and nanodelivery system.Journal of nanobiotechnology · 2023Review
- Boronates as hydrogen peroxide-reactive warheads in the design of detection probes, prodrugs, and nanomedicines used in tumors and other diseases.Drug delivery and translational research · 2023Review
- Recent advances in smart nanoplatforms for tumor non-interventional embolization therapy.Journal of nanobiotechnology · 2022Review
- Smart nanomaterials for cancer diagnosis and treatment.Nano convergence · 2022Review
- Nanomedicine-enabled chemotherapy-based synergetic cancer treatments.Journal of nanobiotechnology · 2022Review
- Glucose Metabolism Intervention-Facilitated Nanomedicine Therapy.International journal of nanomedicine · 2022Review
- Mitochondria-Targeting Chemodynamic Therapy Nanodrugs for Cancer Treatment.Frontiers in pharmacology · 2022Review
- GSH/ROS Dual-Responsive Supramolecular Nanoparticles Based on Pillar[6]arene and Betulinic Acid Prodrug for Chemo-Chemodynamic Combination Therapy.Molecules (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.